Cite
MLA Citation
Erika J Lampert et al.. “Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses.” Journal for immunotherapy of cancer, vol. 8, no. 2, 2020, p. . http://access.bl.uk/ark:/81055/vdc_100127560009.0x000024